報價延遲最少15分鐘:2025/06/03 17:43 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.94 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.55/-1.96
|
|
企業價值
2.88B
|
| 資產負債 |
|
每股賬面淨值
3.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 17:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |